About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Non-Small Cell Lung Cancer Patients may Not Get Survival Benefit With Sorafenib

by Kathy Jones on January 10, 2012 at 7:44 PM
Font : A-A+

 Non-Small Cell Lung Cancer Patients may Not Get Survival Benefit With Sorafenib

Data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine reveals that sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory".

Patients with lung cancer and a KRAS mutation are believed to have a poor prognosis and may not benefit from treatment with epidermal growth factor receptor tyrosine kinase inhibitors, according to study author Wouter W. Mellema, M.D., a doctoral candidate at VU University Medical Center in Amsterdam.

Advertisement

"There is a great need for targeted treatment options for patients with non-small cell lung cancer (NSCLC) with a KRAS mutation," he said.

In the phase 2, multicenter study conducted in the Netherlands, researchers assigned 57 patients with NSCLC and a KRAS mutation to 400 mg of sorafenib twice daily.
Advertisement

At six weeks, Mellema and colleagues reported a rate of no progression of 52.6 percent. Fifteen patients stopped treatment before six weeks — 10 of whom stopped due to clinical progression. Median progression-free survival was 2.3 months, and median overall survival was 5.3 months. The researchers reported that 14 patients are still alive.

"Sorafenib could be a useful drug in this patient population by inhibiting the growth-stimulating signal of the RAS protein," Mellema said. "However, although sorafenib showed relevant activity, the outcome was unsatisfactory."

Mellema and his team had conducted a pilot study in 10 patients, which showed "very promising results. Unfortunately, the results of the phase 2 study were less optimistic. We expected that progression-free survival and overall survival would be better [in the phase 2 study]," Mellema said.

He suggested that the KRAS mutation causes early progression by stimulating cell growth through an alternative pathway. "Future studies currently in preparation in our group should focus on simultaneous inhibition of these pathways," he said.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Lung Biopsy Lung Cancer Cancer and Homeopathy Parkinsons Disease Surgical Treatment Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Cancer Facts Asbestosis Cancer 

Recommended Reading
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can ......
Pneumonia
Pneumonia is a lung infection that can be caused by a bacteria or a virus. It causes inflammation .....
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lympho...
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukem...
Asbestosis
Asbestosis is a chronic inflammatory lung disease that occurs due to long term exposure to asbestos ...
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by ex...
Lung Biopsy
The procedure by which tissue samples are obtained from the lung is known as lung biopsy. The biopsy...
Lung Cancer
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use